古塞奇尤单抗暴露-反应关系及血清蛋白质组学预测生物标志物探索
血清蛋白质组学未能识别早期预测应答的生物标志物。
要点
- 古塞奇尤单抗谷浓度与PASI应答相关,最佳稳态谷浓度为1.6 μg/mL
- 体重≥90 kg患者谷浓度较低但临床结局仍可接受,不建议常规增加剂量
- 血清蛋白质组学未发现可区分未来应答的早期差异蛋白
核心结论
- 古塞奇尤单抗存在暴露-反应关系,最佳稳态谷浓度为1.6 μg/mL。
- 治疗药物监测是优化古塞奇尤单抗治疗的有前景策略。
- 血清蛋白质组学未识别出预测生物标志物候选。
研究设计与样本
- 亚队列包括38例古塞奇尤单抗患者(第0周和第4周)、6例未接受系统治疗的银屑病患者和4例健康对照。
主要发现
- 古塞奇尤单抗谷浓度与临床应答在第4周、第12周和稳态(≥20周)相关。
- 从治疗第4周起,最佳应答者(PASI≤2)的谷浓度显著高于次优应答者。
- 体重≥90 kg患者谷浓度较低、绝对PASI较高,但临床结局仍处于可接受至优秀范围。
关键数值与推荐
- 最佳稳态谷浓度定义为1.6 μg/mL。
- 最佳应答定义为PASI≤2。
临床怎么用
- 可考虑通过治疗药物监测将古塞奇尤单抗稳态谷浓度维持在1.6 μg/mL以优化应答。
- 不建议对体重≥90 kg患者常规增加古塞奇尤单抗剂量。
- 目前不推荐基于血清蛋白质组学标志物进行应答预测。
局限性
- 蛋白质组学分析仅基于38例患者的亚队列,样本量有限。
- 未发现早期差异表达蛋白,作者建议在更大队列中重复蛋白质筛查。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Response to biologics in psoriasis varies in real-world settings. Serum biomarkers could aid biologic selection and dose modifications to improve patient outcomes while encouraging cost-effective care. OBJECTIVES: To explore the exposure-response relationship for guselkumab (GUS), to define a GUS concentration target for optimal response and to evaluate the potential of serum protein levels as predictive biomarker candidates. METHODS: This is a prospective, multicentric, cohort study in psoriasis patients treated with GUS. Serum GUS trough concentrations (TCs) collected at multiple timepoints were measured using an in-house immunoassay. Next, proximity extension assay technology (Target 96 Inflammation Panel Olink®) was used to measure serum protein levels in a subcohort including 38 GUS patients (week 0 and week 4), six psoriasis patients naive for systemic treatment and four healthy controls. RESULTS: Seventy-five patients participated and 400 samples were collected. Guselkumab TCs and clinical response were correlated at week 4, week 12 and in steady-state (≥20 weeks). Optimal responders (Psoriasis Area and Severity Index [PASI] ≤ 2) had significantly higher TCs than suboptimal responders from week 4 onwards in treatment. An optimal steady-state TC of 1.6 μg/mL was defined. Although TC and absolute PASI were lower and worse, respectively, in patients weighing ≥90 kg, clinical outcomes referred to desirable to excellent PASI ranges. Therefore, we do not recommend systematically higher GUS doses in obese patients. We could not reveal early differentially expressed proteins to distinguish future optimal from suboptimal responders. CONCLUSIONS: We demonstrated an exposure-response relationship for GUS and an optimal steady-state TC of 1.6 μg/mL in real-world psoriasis patients. Hereby, we deliver more evidence that therapeutic drug monitoring poses a promising strategy in optimizing GUS treatment. No biomarker candidates were identified through serum proteomics. We propose protein screening should be repeated in larger cohorts to continue the quest for predictive biomarkers.
引用
- Soenen R, Schots L, Wang Z, et al. Exposure-response relationship of guselkumab and the potential of serum proteomics in identifying predictive biomarker candidates in psoriasis. J Eur Acad Dermatol Venereol. 2024. PMID: 38717285. doi:10.1111/jdv.20074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。